Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis

Modern Rheumatology

Volumn 24, Issue 3, 2014, Pages 405-409

  Miyagawa, Ippei ^a   Nakayamada, Shingo ^a   Saito, Kazuyoshi ^a   Hanami, Kentaro ^a   Nawata, Masao ^a   Sawamukai, Norifumi ^a   Nakano, Kazuhisa ^a   Yamaoka, Kunihiro ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

AA Amyloidosis; Rheumatoid Arthritis; Tocilizumab; Treatment

Indexed keywords

AMYLOID A PROTEIN; AZATHIOPRINE; ETANERCEPT; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN-6 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; SERUM AMYLOID A;

ADULT; AGED; AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN URINE LEVEL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPLICATION; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; HUMANS; RECEPTORS, INTERLEUKIN-6; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME;

EID: 84900446713     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.844294     Document Type: Article

References (26)

1. Vasala M. Immonen K. Kautiainen H. Hakala M. More evidence of declining incidence of amyloidosis associated with infl ammatory rheumatic diseases. Scand J Rheumatol. 2010; 39(6): 461-5
2. Lachmann H J Goodman H J Gilbertson J A Gallimore J R Sabin C A Gillmore JD Hawkins PN. Natural history and outcome in systemic AA amyloidosis. NEngl J Med. 2007; 356(23): 2361-71
3. Gillmore JD. Lovat LB. Persey MR. Pepys MB. Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358(9275): 24-9
4. Elkayam O. Hawkins PN. Lachmann H. Yaron M. Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infl iximab. Arthritis Rheum. 2002; 46(10): 2571-3
5. Gottenberg JE. Merle-Vincent F. Bentaberry F. Allanore Y Berenbaum F. Fautrel B et al. Anti-Tumor necrosis factor alpha therapy in fi fteen patients with AA amyloidosis secondary to infl ammatory arthritis: Follow-up report of tolerability and effi cacy. Arthritis Rheum. 2003; 48(7): 2019-24
6. Drewe E. Huggins ML. Morgan AG. Cassidy MJ. Powell RJ. Treatment of renal amyloidosis with etanercept in tumor necrosis factor receptor-Associated periodic syndrome. Rheumatology(Oxford). 2004; 43(11): 1405-8
7. Kuroda H. Otaki Y. Sato H. Fujiwara T. Nakatsue T. Murakami S et al. Acase of AA amyloidosis associated with rheumatoid arthritis eff ectively treated with Infl iximab. Rheumatol Int. 2008; 28(11): 1155-9
8. Kuroda T. Wada Y. Kobayashi D. Murakami S. Sakai T. Hirose S. et al. Eff ective anti-TNF-ectively treated with Infl iximab. infl iximsustaind decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J. Rheumatol. 2009; 36(11): 2409-15
9. Nakamura T. Higashi S. Tomoda K. Tsukano M. Shono M. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2010; 29(12); 1395-401
10. Fernandes-Nebro A. Olive A. Castro MC. Varela AH. Riera E Irigoyen MV. et al. Long-Term TNF-Alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010; 123(5): 456-61
11. Nishimoto N. Hashimoto J. Miyasaka N. Yamamoto K. Kawai S Takeuchi T. et al. Study of active controlled monotherapy used for rheumatoid arthritis an IL-6 receptor antibody(SAMURAI): Evidence of clinical and radiographic benefi t from an X ray readerblinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007; 66(9): 1162-7
12. Nishimoto N. Yoshizaki K. Miyasaka N. Yamamoto K. Kawai S Takeuchi T. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: Multicenter double-blind placebo-controlled trial. Arthritis Rheum. 2004; 50(6): 1761-9
13. Maini RN. Taylor PC. Szechinski J. Pavelka K. Broll G. Balint G. et al. Double-blind randomized controlled clinical trials of the interleukin-6 receptor antagonist tocilizumab in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54(9): 2817-29
14. Nishimoto N. Kishimoto T. Interleukin 6: From bench to bedside. N at Clin Pract Rheumatol. 2006; 2(11): 619-26
15. Nishida S. Hagihara K. Shima Y. Kawai M. Kuwahara Y Arimitsu J et al. Rapid improvement of AA amyloidosis with humanized anti-interleukin 6 receptor treatment: Nn Rheum Dis. 2009; 68(7): 1235-6
16. Sato H. Sakai T. Sugaya T. Otaki Y. Aoki K. Ishii K. et al. Tocilizumab dramatically ameliorated life-Threating diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009; 28(9): 1113-6
17. Inoue D. Arima H. Kawanami C. Takiuchi Y. Nagano S. Kimura T et al. Excellent therapeutic eff ect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010; 29(10): 1195-7
18. Okuda Y. Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody tocilizumab to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006; 54(9): 2997-3000
19. Arnett FC. Edworthy SM. Bloch DA. McShane DJ. Fries JF Cooper NS. et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3): 315-24
20. Levey A S Eckardt K U Tsukamoto Y. Levin A. Coresh J. Rossert J et al. Defi nition and classifi cation of chronic kidney disease: Position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6): 2089-100
21. Hagihara K. Nishikawa T. Sugamata Y. Song J. Isobe T. Taga T. Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005; 10(11): 1051-63
22. Urieli-Shoval S. Linke RP. Matzner Y. Expression and function of serum amyloid A amajor acute-phase protein in normal and disease states. Curr. Opin Hematol. 2000; 7(1): 64-9
23. Niewold T A Gruys E. Arakawa T. Shirahama T. Kisilevsky R. Recombinant human tumor necrosis factor-Alpha(rhTNF-Alpha) and rhTNF-Alpha analogue enhance amyloid deposition in the Syrian hamster. Scand J Immunol. 1993; 37(1): 29-32
24. Obici L. Raimondi S. Lavatelli F. Bellotti V. Merlini G. Susceptibility to AA Amyloidosis in Rheumatic Diseases: Critical Overview. Arthritis Rheum. 2009; 61(10): 1435-40
25. Hagihara K. Nishikawa T. Isobe T. Song J. Sugamata Y Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A(SAA) gene when stimulated with proinfl ammatory cytokines as analyzed with an SAA isoform real-Time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004; 314: 363-9
26. Yoshizaki K. Pathogenic analysis of chronic infl ammatory disease based on the clinical results by IL-6 blocking therapy(in Japanese). Nihon Rinsho Meneki Gakkai Kaishi 2008; 3: 104-12